التفاصيل البيبلوغرافية
| العنوان: |
Prognostic Factors in Patients Receiving Neoadjuvant 5-Fluorouracil plus Cisplatin for Advanced Esophageal Cancer (JCOG9907). |
| المؤلفون: |
Yokota, Tomoya, Ando, Nobutoshi, Igaki, Hiroyasu, Shinoda, Masayuki, Kato, Ken, Mizusawa, Junki, Katayama, Hiroshi, Nakamura, Kenichi, Fukuda, Haruhiko, Kitagawa, Yuko |
| المصدر: |
Oncology; Aug2015, Vol. 89 Issue 3, p143-151, 9p, 1 Diagram, 3 Charts, 2 Graphs |
| مصطلحات موضوعية: |
ANTINEOPLASTIC agents, ACADEMIC medical centers, BLOOD testing, COMBINATION drug therapy, CHI-squared test, CISPLATIN, CLINICAL trials, COMBINED modality therapy, CONFIDENCE intervals, ESOPHAGEAL tumors, FLUOROURACIL, MULTIVARIATE analysis, REGRESSION analysis, RESEARCH funding, RISK assessment, SQUAMOUS cell carcinoma, TUMOR classification, TREATMENT effectiveness, PROPORTIONAL hazards models, PATIENT selection, DATA analysis software, DESCRIPTIVE statistics, KAPLAN-Meier estimator, THERAPEUTICS, PROGNOSIS |
| مستخلص: |
Objective: Neoadjuvant chemotherapy with 5-fluorouracil plus cisplatin and subsequent esophagectomy with two- to three-field lymphadenectomy is a standard treatment for patients with clinical stage II/III squamous cell carcinoma (SCC) of the esophagus. This study investigates the prognostic factors for patients who received neoadjuvant chemotherapy. Methods: Of 164 patients assigned to receive neoadjuvant chemotherapy in the JCOG9907 trial, multivariate analyses were performed for 159 and 149 patients to evaluate the preoperative and the combined preoperative and postoperative prognostic factors, respectively. Results: The multivariate analyses using preoperative factors showed that clinical stage T3 [vs. cT1-2; hazard ratio (HR) 3.60, p = 0.0007] and serum albumin (Alb) <4.0 g/dl (vs. ≥4.0 g/dl; HR 2.29, p = 0.0005) were associated with a poor prognosis. Four independent prognostic factors were identified by multivariate analysis of both preoperative and postoperative factors: pathological curability B (pB; R0 with stage IV or pD < pN) or pC [microscopic or macroscopic residual tumor (R1/R2)] [vs. pA (R0); HR 1.93, p = 0.015], pathological stage N1 (vs. pN0; HR 3.86, p = 0.0012), cT3 (vs. cT1-2; HR 2.80, p = 0.0073), and serum Alb <4.0 g/dl (vs. ≥4.0 g/dl; HR 2.03, p = 0.0069). Conclusions: Preoperative cT stage, Alb, and postoperative pathological findings are independent prognostic factors for patients undergoing neoadjuvant chemotherapy for advanced thoracic esophageal SCC. This analysis may aid in stratification according to individual patient risk. © 2015 S. Karger AG, Basel [ABSTRACT FROM AUTHOR] |
|
Copyright of Oncology is the property of Karger AG and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
